IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization

Cytokine

Volumn 56, Issue 3, 2011, Pages 804-810

  Han, Kai ping ^a   Zhu, Xiaoyun ^a   Liu, Bai ^a   Jeng, Emily ^a   Kong, Lin ^a   Yovandich, Jason L ^b   Vyas, Vinay V ^b   Marcus, Warren D ^a   Chavaillaz, Pierre Andre ^a   Romero, Christian A ^a   Rhode, Peter R ^a   Wong, Hing C ^a  

^a ALTOR BIOSCIENCE CORPORATION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD8 + T lymphocytes; CHO cell expression; IL 15 receptor fusion protein; Interleukin 15 superagonist; NK cells

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G1; INTERLEUKIN 15; INTERLEUKIN 15 INTERLEUKIN 15 RECEPTOR ALPHA FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHO CELL; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PURIFICATION; FEMALE; IMMUNOSTIMULATION; ION EXCHANGE CHROMATOGRAPHY; MALE; MAMMAL CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; BODY WEIGHT; CELL SEPARATION; CHO CELLS; CHROMATOGRAPHY, GEL; CRICETINAE; CRICETULUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTES; MALE; MAMMALS; MICE; MICE, INBRED C57BL; MUTANT PROTEINS; ORGAN SIZE; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC;

CRICETULUS GRISEUS; MAMMALIA; MUS;

EID: 81455158710     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.09.028     Document Type: Article

References (20)

1. Ma A., Koka R., Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006, 24:657-679.
2. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006, 6:595-601.
3. Fehniger T.A., Cooper M.A., Caligiuri M.A. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002, 13:169-183.
4. Cheever M.A. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008, 222:357-368.
5. Zhu X., Marcus W.D., Xu W., Lee H.I., Han K., Egan J.O., et al. Novel human interleukin-15 agonists. J Immunol 2009, 183:3598-3607.
6. Bergamaschi C., Rosati M., Jalah R., Valentin A., Kulkarni V., Alicea C., et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 2008, 283:4189-4199.
7. Huntington N.D., Legrand N., Alves N.L., Jaron B., Weijer K., Plet A., et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009, 206:25-34.
8. Wong R.L., Liu B., Zhu X., You L., Kong L., Han K.P., et al. Interleukin-15:interleukin-15 receptor alpha scaffold for creation of multivalent targeted immune molecules. Protein Eng Des Sel 2011, 24:373-383.
9. Mortier E., Quemener A., Vusio P., Lorenzen I., Boublik Y., Grotzinger J., et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15×IL-15R alpha fusion proteins. J Biol Chem 2006, 281:1612-1619.
10. Rubinstein M.P., Kovar M., Purton J.F., Cho J.H., Boyman O., Surh C.D., et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci USA 2006, 103:9166-9171.
11. Stoklasek T.A., Schluns K.S., Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006, 177:6072-6080.
12. +/CD44 high T cells and its antitumor action. J Immunol 2008, 180:2099-2106.
13. + T cells. Cancer Res 2008, 68:2972-2983.
14. Bessard A., Sole V., Bouchaud G., Quemener A., Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009, 8:2736-2745.
15. Mosquera L.A., Card K.F., Price-Schiavi S.A., Belmont H.J., Liu B., Builes J., et al. In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. J Immunol 2005, 174:4381-4388.
16. Hughes M.S., Yu Y.Y., Dudley M.E., Zheng Z., Robbins P.F., Li Y., et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 2005, 16:457-472.
17. Belmont H.J., Price-Schiavi S., Liu B., Card K.F., Lee H.I., Han K.P., et al. Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein. Clin Immunol 2006, 121:29-39.
18. Ward A., Anderson M., Craggs R.I., Maltby J., Grahames C., Davies R.A., et al. E. coli expression and purification of human and cynomolgus IL-15. Protein Expr Purif 2009, 68:42-48.
19. Bouchaud G., Garrigue-Antar L., Sole V., Quemener A., Boublik Y., Mortier E., et al. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol 2008, 382:1-12.
20. Liu H., Gaza-Bulseco G., Faldu D., Chumsae C., Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008, 97:2426-2447.